Showing results (561-570 of 734) with videos related to
Sort By:
Pageof 74
Mayo Clinic Proceedings|July 5, 2022
Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell TherapyNaba Farooqui, Janina Paula T Sy-Go, Jing Miao, et al.Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2006
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disordersAnne J Novak, Deanna M Grote, Steven C Ziesmer, et al.Haematologica|November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppressionSean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.Leukemia & Lymphoma|October 15, 2020
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemiaMadugodaralalage D S K Gunaratne, Alexander J Sahakian, Jithma P Abeykoon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.Pageof 74